Abstract Number: 139 • 2015 ACR/ARHP Annual Meeting
One-Year Cost of Etanercept, Adalimumab, and Infliximab per Treated Patient with Chronic Inflammatory Arthritides in US Veterans
Background/Purpose: Understanding the relative cost of tumor necrosis factor inhibitors (TNFi) can improve resource allocation from a payer’s perspective. Limited data exists in the VA…Abstract Number: 140 • 2015 ACR/ARHP Annual Meeting
Identifying Psoriatic Arthritis and Ankylosing Spondylitis Patients Responsible for the Highest Costs of Care: Data from a Large US Cohort
Background/Purpose: The economic burden of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in the biologics era is not well understood in the US population. Using…Abstract Number: 141 • 2015 ACR/ARHP Annual Meeting
Improved Follow-up of Hypertension in Rheumatology Patients: Results of a Pilot
Background/Purpose: Hypertension is the most common and most modifiable cardiovascular disease (CVD) risk factor, yet it is uncontrolled in ½ of US adults. Hypertension management…Abstract Number: 142 • 2015 ACR/ARHP Annual Meeting
Exploration of General Practioners’ Difficulties with Methotrexate and Anti-TNF Therapies in Routine Practice
Background/Purpose: Chronic inflammatory arthritis affects around 1% of the general population. Disease-modifying drugs like methotrexate (MTX) and in second-line anti tumor necrosis factor (anti-TNF) therapy…Abstract Number: 143 • 2015 ACR/ARHP Annual Meeting
Fiber Optic Intubation in Patients with Rheumatoid Arthritis Who Had a Surgical Procedure
Background/Purpose: Fiber optic intubation is the preferred method of airway management during anesthetic procedures for patients with RA. The purpose of our study was to…Abstract Number: 144 • 2015 ACR/ARHP Annual Meeting
One-Year Costs Following Switching Versus Dose-Escalation Among Prevalent Tumor Necrosis Factor Inhibitors Used for Rheumatoid Arthritis
Background/Purpose: Switching a biologic treatment or escalating biologic doses are common approaches used upon biologic treatment failure. The objective of this study was to estimate…Abstract Number: 145 • 2015 ACR/ARHP Annual Meeting
Economic Burden of Switching to an Anti-Tumor Necrosis Factor (anti-TNF) Versus a Non-Tumor Necrosis Factor (non-TNF) Biologic Therapy Among Patients with Rheumatoid Arthritis
Background/Purpose: Real world studies comparing the healthcare utilization of anti-TNFs vs. non-TNFs as the next alternative after the failure of the first anti-TNF are scarce.…Abstract Number: 146 • 2015 ACR/ARHP Annual Meeting
Rates of Lipid Testing and Statin Prescription Filling Among U.S. Medicaid Recipients with SLE, 2007-2010
Background/Purpose: Given high cardiovascular disease (CVD) risks in SLE patients, lipid testing and statin prescription are widely advocated for those with elevated risks. We examined…Abstract Number: 147 • 2015 ACR/ARHP Annual Meeting
Fatigue, Coping, Sleeping Disorders and Productivity Were Still Not Frequently Reported in Rheumatoid Arthritis Trials Published in 2014-2015: A Systematic Literature Review
Background/Purpose: In a systematic literature review (SLR), frequency of patients reported outcomes (PROs) related with rheumatoid arthritis (RA) was evaluated between 2005 and 2007 (1).…Abstract Number: 148 • 2015 ACR/ARHP Annual Meeting
An Evaluation of the Virtual Monitoring Clinic, a Novel Nurse-Led Telemonitoring Service for Monitoring Patients with Stable Rheumatoid Arthritis
Background/Purpose: To study the clinical and patient reported outcomes of the Virtual Monitoring Clinic (VMC), which is novel nurse-led telemonitoring cum pharmacy medication home delivery…Abstract Number: 149 • 2015 ACR/ARHP Annual Meeting
Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus (SLE) Initiating Treatment with Belimumab in a US Commercially Insured Database: 2010-2014
Background/Purpose: Belimumab, a B-lymphocyte stimulator, was FDA-approved March 2011 for the treatment of adult patients with active, autoantibody-positive SLE receiving standard of care (SOC) medications.…Abstract Number: 150 • 2015 ACR/ARHP Annual Meeting
A Preliminary Consensus on Core Outcome Domains for Total Joint Replacement Clinical Trials: An Omeract-Based Study
Background/Purpose: Outcomes Measures in Rheumatology Trials (OMERACT) has developed a framework based on the WHO’s International Classification of Functioning, Disability, and Health (ICF) conceptual model. …Abstract Number: 151 • 2015 ACR/ARHP Annual Meeting
Residual Synovitis in Ultrasound (US) Is Associated with an Evolution Towards Rheumatoid Arthritis (RA) in Patients with Inflammatory Polyarthralgia without ANTI-Citrulinated Antibodies (ACPA)
Background/Purpose: In ACPA positive patients, subclinical synovitis as observed by US has been demonstrated in pre RA patients and seems to be predictive for future…Abstract Number: 152 • 2015 ACR/ARHP Annual Meeting
Anti-CCP Positive Patients without Clinical Synovitis Progress If Ultrasound Positive
Background/Purpose: To determine whether ultrasound can identify which anti-cyclic citrullinated peptide (anti-CCP) antibody positive patients with musculoskeletal (MSK) symptoms and without clinical synovitis progress to…Abstract Number: 153 • 2015 ACR/ARHP Annual Meeting
Utility of Ultrasound Synovitis Assessment As a Predictor of Flares in Clinically Inactive Joints
Background/Purpose: Several ultrasound (US) studies have shown a high frequency of inflammation in clinically inactive joints of rheumatoid arthritis (RA)patients. There is controversy in the…
ACR Meeting Abstracts